9 + 11 = Possible 3: Can A Stryker-Boston Scientific Combo Work?

Unconfirmed rumors of Stryker having approached Boston Scientific about a takeover bid raised eyebrows all around, not least because the move – reported on June 11 – was so unexpected. But would a combination of the medtech industry's No. 9 and No. 11, to create a broad-scale portfolio with very little product overlap, make strategic sense? Reactions have been mixed.

Question marks
Rumors of a Stryker/Boston Scientific merger have raised questions about whether a bigger combined company will work

When the rumors about Stryker Corp. making a play for Boston Scientific Corp. first emerged on June 11, the reaction was of unified surprise. The report, by the Wall Street Journal citing sources close to the matter, led to Boston Scientific's share value jumping 17% during intraday trading and Stryker's shares dipping slightly, while market spectators tried to figure out if a possible merger between the industry's No. 9 (Stryker, its ranking in the MTI 100 league table) and No. 11 (Boston Scientific) could actually work.

Based on their respective 2017 full-year revenue, a merger between Stryker and Boston Scientific will result in a company with...

More from Deals

More from Business